Chiesi Group will acquire KalVista Pharmaceuticals for $1.9B after its FDA approval in July 2025 for an oral hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results